Analytical methods
Sanger-sequencing of coding regions and their flanking intronic sequences is used in combination with pre-screening methods, such as DGGE, DHPLC, CSCE and so on. For a subset of genes, the multiplex ligation-dependent probe amplification (MLPA) technique is used in order to identify deletions or duplications of whole exons.
Analytical validation
Sequencing of both strands. When a mutation is identified, it is recommended to validate this in an independent experiment by direct sequencing or MLPA (in case of a large deletion/duplication) using a freshly prepared DNA dilution.
Estimated frequency of the disease
Incidence at birth ('birth prevalence') or population prevalence. If known to be variable between ethnic groups, please report: An epidemiological study on idiopathic DCM from 1989 estimated the incidence of the disease at 6 per 100 000 per year and the prevalence at 36.5 per 100 000. 6 However, a recent review suggests that these numbers are likely to underestimate the condition significantly. 7 No additional, up-to-date epidemiological studies are available.
Diagnostic setting
Yes No
The most frequently mutated DCM genes are TTN, LMNA, MYH7 and TNNT2. A recent study of a small cohort of idiopathic DCM patients reported that the frequency of TTN mutations was 25% in familial DCM and 18% in apparently sporadic cases. 1 MYH7 and TNNT2 mutations are identified with a frequency of 4-5% and 3%, respectively. 8 LMNA mutations are also frequently detected in up to 6% of cases and in particular in the subgroup of idiopathic DCM associated with conduction disease (30-33%). 9, 10 In certain populations, specific mutations may be overrepresented due to a common founder mutation, for example, the LMNA p.Ser143Pro in 7% of the Finnish idiopathic DCM population or the PLN p.Arg14del in up to 15% of Dutch idiopathic DCM patients. 11, 12 Several studies have reported that DCM patients carrying more than one disease-associated mutation have an early onset, severe disease expression and a bad prognosis, which is most likely due to a gene-dosage effect. [13] [14] [15] [16] It is expected that next-generation sequencing techniques will identify an increasing number of patients with such complex genotypes. Specificity:
TEST CHARACTERISTICS
Negative predictive value:
2.1 Analytical sensitivity (proportion of positive tests if the genotype is present) Almost 100%, also depending on the analytical method used.
Preferential amplification of one allele may occur when one of the primers is located on a SNP. To prevent this, primers have to be verified using the SNPCheck software (https://ngrl.manchester.ac.uk/ SNPCheckV3/snpcheck.htm) yearly.
Analytical specificity (proportion of negative tests if the genotype is not present)
Almost 100%, depending on the analytical method used.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity is dependent on variable factors such as age, disease manifestation and family history.
Mutational analysis of the 51 currently known DCM genes may explain the genetic background in up to 50% of familial DCM cases. 1 The yield of genetic testing varies considerably. The mutation detection rates for the most prevalent DCM-related genes are: TTN: 18-25%, LMNA: 6%, MYH7: 4-5%, MYH6: 3-4%, MYBPC3: 2-4%, TNNT2: 3% and BAG3: 2-3%. 5, 8 If cardiac conduction disease accompanies idiopathic DCM, an LMNA gene mutation can be identified in up to one-third of cases. 9, 10 However, large differences in the yield of genetic testing have been observed, which are most likely explained by differences in sample size, variability in frequency of founder mutations and ethnicity.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity is dependent on variable factors such as age, disease manifestation and family history.
As the penetrance of inherited DCM is incomplete and age dependent, the clinical specificity is o100%.
Positive clinical predictive value (life-time risk to develop the disease if the test is positive)
Probably reaches 100% at advanced age because the clinical penetrance is age dependent (o20 years: 10%, 20-30 years: 34%; 30-40 years: 60%; 440 years: 90%), with onset generally in the fourth decade of life. 17 
Negative clinical predictive value (probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: If a pathogenic mutation is found in the index patient, the risk of being a carrier for a first-degree relative is 50% (assuming autosomaldominant inheritance of a familial mutation). If a pathogenic mutation is identified in the index patient, and this mutation is absent in another family member, this family member is generally believed not to be at increased risk for developing DCM. However, because carriership of multiple putative disease-causing mutations in more than one gene has been reported, it cannot be excluded that this mutation-negative family member may carry a still unidentified DCM-related mutation. The chance of carrying such an additional DCM-related mutation is believed to be o3%. 7, 15, 16 Index case in that family had not been tested: Idiopathic DCM is believed to be familial in about 30-50% of cases. Therefore, if an index patient has been clinically diagnosed with idiopathic DCM, and no genetic test has been performed, the chance for a first-degree relative to develop DCM may reach up to 15-25%.
3. CLINICAL UTILITY 3.1 (Differential) diagnostics: the tested person is clinically affected (To be answered if in 1.9 'A' was marked)
Can a diagnosis be made other than through a genetic test?
No & (continue with 3.1.4) Yes 2
Comment: The clinical diagnosis of familial DCM is generally made by echocardiography based upon the criteria proposed by Mestroni et al. 18 ; that is, a reduced ejection fraction of the left ventricle (o0.45; 42 SD) and/or fractional shortening (o25%; 42 SD); left ventricular end diastolic diameter 4117% of the predicted value (corrected for age and body surface area). However, it is of great importance to exclude other disorders that may give rise to phenocopies. Therefore, additional investigations (imaging modalities and blood testing) have to be carried out to exclude, for example, ischemic heart disease, diabetes and thyroid disease.
3.1.2 Describe the burden of alternative diagnostic methods to the patient Electrocardiography, echocardiography and magnetic resonance imaging are non-invasive imaging techniques with negligible risks and little inconvenience to the patient.
If DCM is diagnosed using these methods, additional techniques (CT-angiography and coronary angiography) have to be used to exclude other causes such as coronary artery disease.
3.1.3
How is the cost-effectiveness of alternative diagnostic methods to be judged? When a pathogenic mutation is identified in an index patient, cascade genetic screening ( ¼ targeted genetic testing for the identified mutation in the family) can be offered to first degree, apparently healthy relatives, to establish whether they are mutation carriers or not.
Mutation-carrying relatives are advised to be screened regularly by a cardiologist to detect early cardiac disease in order to initiate timely treatment. In addition, specific advice regarding physical or occupational activities might be discussed, as well as general lifestyle advices.
Non-mutation carriers can be reassured and dismissed from regular clinical follow-up if the DCM phenotype in that family is consistent with carriership of a single mutation. This method has been shown to be cost-effective for HCM, but no formal cost-effectiveness studies in DCM are available yet. 19 3.1. Possible exceptions are LMNA gene mutation carriers, who may benefit from early implantable cardioverter defibrillator (ICD) therapy if they develop conduction disease. 20 Moreover, a recent study showed that male patients and patients with either nonsustained ventricular tachycardias or left ventricular ejection fraction of o45% carrying a non-missense mutation in LMNA have a higher risk for developing malignant ventricular arrhythmias. 21 
Predictive Setting:
The tested person is clinically unaffected but carries an increased risk based on family history (To be answered if in 1.9 'B' was marked)
Will the result of a genetic test influence lifestyle and prevention?
If the test result is positive, regular cardiological evaluation is recommended to detect signs of DCM and initiate early medical treatment when indicated. The treatment might also include pacemaker and/or ICD implantation. Advice regarding lifestyle and physical activity is also provided. In addition, mutation carriers will receive genetic counselling on risks for their offspring and other close relatives. If the genetic test result is negative, family members without the mutation can be discharged from regular cardiological follow-up. However, because carriership of multiple putative disease-causing mutations in more than one gene have been reported, it cannot be excluded that this mutation-negative family member may carry a still unidentified DCM-related mutation (see also 2.6). Yes, a positive test in the index patient enables the possibility of predictive cascade genetic screening ( ¼ targeted testing for the identified mutation in the family). Non-carriers can be dismissed from regular cardiological evaluation and this results in saving the costs of cardiological investigations, unless carriership of multiple mutations can be expected (see also 2.6).
When the test in the index patient is negative, all relatives are advised to continue regular cardiological follow-up.
3.3.3 Does a positive genetic test result in the index patient enable a predictive test in a family member? Yes, once a pathogenic mutation is identified, a predictive genetic test is possible in family members.
Prenatal diagnosis
(To be answered if in 1.9 'D' was marked) 3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnosis? Prenatal genetic diagnosis in DCM is technically possible when a pathogenic mutation has been identified. However, requests for prenatal diagnosis in late-onset genetic disease are uncommon and only rarely performed. It is not actively offered in non-syndromic late-onset DCM. Recently, pre-implantation genetic diagnosis has been reported in a DCM family. 22 
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe).
The major advantage is that close relatives who are under regular cardiological surveillance can be dismissed from regular follow-up once it has been proven that they do not carry the mutation present in the index patient.
